Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.
To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.
|08/06/2021||Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma||Press Release|
|06/04/2021||Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting||Press Release|
|05/03/2021||Ichnos Sciences Presents Positive Data from Ongoing Phase 2b Study of Telazorlimab in Atopic Dermatitis at the 2021 SID Virtual Meeting||Press Release|
|04/05/2021||Ichnos Sciences Appoints Cyril Konto, M.D., Chief Medical Officer||Press Release|
|03/02/2021||Ichnos Sciences Appoints Michael D. Price as CFO||Press Release|
|01/14/2021||Ichnos Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference||Press Release|
|09/22/2020||Ichnos Sciences Adds Lawrence Olanoff, M.D., Ph.D., to Board of Directors||Press Release|
|05/05/2020||Ichnos Sciences appoints David Lubner to Board of Directors||Press Release|
|02/05/2020||Ichnos expands leadership team with appointment of Gabriela Gruia, M.D. as Chief Development Officer||Press Release|
|12/04/2019||Ichnos Sciences expands leadership team with key appointments||Press Release|
The links above are provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.